ERBB2 and colonic neoplasm: However, the third generation of ERBB2 (HER-2/neu)-targeting CAR-T cells, which are controlled by 4-1BB, CD28 and CD3ζ, induced adverse events in a patient with colon cancer, who experienced respiratory distress within 15 min after the infusion of HER-2/neu-targeting CAR-T cells and had a dramatic pulmonary infiltrate on her chest radiograph [17].